Novo Nordisk receives a number of requests from journalists for information on the GLP-1 hormone and the development of Victoza® (liraglutide), our new type 2 diabetes treatment.
In order to better service these requests, we have developed this online press room as a resource centre for information on GLP-1 hormone, the Victoza® (liraglutide) clinical development programme and related topics.
Take a look back at Novo Nordisk company announcements and press releases about the development of Victoza® (liraglutide).
Find key background information on diabetes, diabetes treatment, and the Victoza® (liraglutide) clinical development programme.
View animations on GLP-1 and Victoza® (liraglutide).
Download a selection B-roll material on Victoza® (liraglutide), documenting the development process for this compound from fermentation to packaging.
Download photos from Victoza® (liraglutide) R&D and the GLP-1 molecule.
Get the answers to frequently asked questions about GLP-1 hormone and the LEAD development programme.
Get a list of relevant links to dig deeper into the areas related to diabetes and Victoza® (liraglutide).
